Why RNA Is Good For Business

By Matthew Pillar, Editor, Bioprocess Online

Early last year, Nutcracker Therapeutics landed a $170 million Series C to further its work developing an RNA drug development platform. That’s pretty noteworthy, considering how easy it is for biopharmaceutical companies to get lost in the cacophony of their peer companies rallying around the therapeutic potential of RNA. Hundreds of biotechs around the globe can count at least one RNA-based therapeutic in their development arsenal, if not because the science is promising, almost certainly because the acronym attracts attention from the investment community.